Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer

Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer

Abstract Background The management of pancreatic cancer (PanCa) is exceptionally difficult due to poor response to available therapeutic modalities. Tubulins play a major role in cell dynamics, thus are important molecular targets for cancer therapy. Among various tubulins, βIII and βIV-tubulin isof...

Full description

Bibliographic Details
Main Authors: Vivek K. Kashyap, Qinghui Wang, Saini Setua, Prashanth K. B. Nagesh, Neeraj Chauhan, Sonam Kumari, Pallabita Chowdhury, Duane D. Miller, Murali M. Yallapu, Wei Li, Meena Jaggi, Bilal Bin Hafeez, Subhash C. Chauhan
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
VERU-111
Pancreatic cancer
β –tubulins
miR-200c
βIII/βIV-tubulin inhibitor
Online Access:http://link.springer.com/article/10.1186/s13046-018-1009-7

Internet

http://link.springer.com/article/10.1186/s13046-018-1009-7

Similar Items